Lantheus Holdings — Valuation, Funding & Investors

We're still building this profile — here is what Pulse has covered.

Latest Pulse

Aug 10, 2026Lantheus Agrees to Up-to-$8B Curium TakeoverLantheus Holdings agreed to be acquired by Curium for $102.50 a share in cash plus contingent value rights worth up to $12.00 more, a deal that could total $8.0 billion.→

Coverage Timeline

newest first

Aug 10, 2026BIG TECHLantheus Agrees to Up-to-$8B Curium TakeoverUp to $8.0B→

All Coverage

BIG TECH· Aug 9, 2026

Lantheus Agrees to Up-to-$8B Curium Takeover

BIG TECHUp to $8.0B

Lantheus Agrees to Up-to-$8B Curium Takeover

Lantheus Holdings agreed to be acquired by Curium for $102.50 a share in cash plus contingent value rights worth up to $12.00 more, a deal that could total $8.0 billion.

Aug 9, 2026BRIEF

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics